Production of anti-self bodies from antibody segment repertories and displayed on phage

Patent Citations (45)

Non-Patent Literature (236)

• Alzari et al., “Three Dimensional Structure Determination of an Anti-2-Phenyloxazolone Antibody: The Role of Somatic Muation and Heavy/Light Chain Pairing in the Maturation of an Immune Response,” EMBO J., 9:3807-3814 (1990).Applicant
• Amit et al., “Three-Dimentional Structure of an Antigen-Antibody Complex at 2.8 Å Resolution,” Science, 233:747-753 (1986).Applicant
• Avrameas, “Natural autoantibodies: from ‘horror autotoxicus’ to ‘gnothi seauton’”, Immunology Today, 12:154-159 (1991).Applicant
• Bass et al., “Hormone Phage: An Enrichment Method for Variant Proteins With Altered Binding Properties”, Proteins, Structure, Function and Genetics, 8:309-314 (1990).Applicant
• Bendtzen et al., “Autoantibodies to cytokines—friends or foes?”, Immunology Today, 11(5):167-169 (1990).Applicant
• Bentley et al., “Human Immunoglobulin Variable Region Genes-DNA Sequences of Two VK Genes and a Pseudogene,” Nature, 288:730-3 (1980).Applicant
• Berman et al., “Content and Organization of the Human Ig VH Locus: Definition of Three New VH Families and Linkage to the Ig CH Locus,” EMBO J, 7:727-738 (1988).Applicant
• Bernard et al., “Genomic Sequence of IGLV1S2, A Human Immunoglobulin Variable Lambda Gene Belonging to Subgroup I,” Nucleic Acids Res, 18:7139 (1990).Applicant
• Bird et al., “Single-Chain Antigen-Binding Proteins,” Science, 242:423-426 (1988).Applicant
• Bouanani, M. et al., “Autoimmunity to Human Thyroglobulin,” Arthritis and Rheumatism, 34(12):1585-1593 (Dec., 1991).Applicant
• Brockly et al., “First Nucleotide Sequence of a Human Immunoglobulin Variable λ Gene Belonging to Subgroup II,” Nucleic Acids Res, 17:3976 (1989).Applicant
• Carter et al., “Improved Oligonucleotide Site-Directed Mutagenesis Using M13 Vectors,” Nucl. Acids Res., 13:4431-4443 (1985).Applicant
• Casali, et al., “Probing the Human B-Cell Repertoire With EBV: Polyreactive Antibodies and CD5+ B Lymphocytes1,2,” Ann. Rev. Immunol., 7:513-535 (1989).Applicant
• Chen et al., “A 16/6 Idiotype-Positive Anti-DNA Antibody Is Encoded By a Conserved VH Gene With No Somatic Mutation,” Arthritis Rheum, 31:1429-1431 (1988).Applicant
• Chothia et al., “Canonical Structures for the Hypervariable Regions of Immunoglobulins,” J. Mol. Biol., 196:901-917 (1987).Applicant
• Chothia et al., “Conformation of Immunoglobulin Hypervariable Regions,” Nature, 342:877-893 (1989).Applicant
• Chothia et al., “Structural Repertoire of the Human VH Segments,” J. Mol. Biol., 227:779-817 (1992).Applicant
• Clackson et al., “Making Antibody Fragments Using Phage Display Libraries,” Nature, 352:624-628 (1991).Applicant
• Cohen et al., “Natural Autoantibodies Might Prevent Autoimmune Disease,” Immunol. Today, 7:363-364 (1986).Applicant
• Cunningham et al., “Antibody engineering—how to be human,” Trends Biotechnol (England), 10(4):112-3 (Apr., 1992).Applicant
• Curti, “Physical barriers to drug delivery in tumors,” Crit. Rev. Oncol . Hematol., (Ireland), 14(1):29-39 (Feb., 1993).Applicant
• Daley et al., “Molecular Characterization of the Human Immunoglobulin vλI Germline Gene Repertoire,” Molecular Immunology, 29:1031-1042 (1992).Applicant
• Davis et al., “Antibody and HIV-1 gp120 Recognition of CD4 Undermines the Concept of Mimicry Between Antibodies and Receptors,” Nature, 358:76-79 (1992).Applicant
• de la Cruz et al., “Immumogenicity and Epitope Mapping of Foreign Sequences via Genetically Engineered Filamentous Phage”, J. Biol. Chem., 263(9):4318-4322 (1988).Applicant
• DeBellis et al., “Regulated Expression of Foreign Genes Fused to lac: Control by Glucose Levels in Growth Medium,” Nucl. Acids Res., 18:1311 (1990).Applicant
• Dejana et al., “Modulation of Endothelial Cell Functions by Different Molecular Species of Interleukin 1,” Blood, 69:695-699 (1987).Applicant
• Dillman et al., “Monoclonal antibodies for treating cancer,” Ann Intern Med (United States,) 111(7):592-603 (Oct., 1989).Applicant
• Ditzel et al., “The nature of the autoimmune antibody repertoire in human immunodeficiency virus type 1 infection”, Proc. Natl. Acad. Sci. USA, 91:3710-3714 (1994).Applicant
• Dower et al., “Retention of Ligand Binding Activity by the Extracellular Domain of the IL-1 Receptor,” J. Immunol., 142:4314-4320 (1989).Applicant
• Eisen, H.N., “Determination of Antibody Affinity for Haptens and Antigens by Means of Fluorescence Quenching,” Meth. Med. Research, 10:115-121 (1964).Applicant
• Embleton et al., “In-Cell PCR from mRNA: Amplifying and Linking the Rearranged Immunoglobulin Heavy And Light Chain V-Genes Within Single Cells,” Nucleic Acids Research, 20:3831-3837 (1992).Applicant
• Foote et al., “Kinetic Maturation of an Immune Response,” Nature, 352:530-532 (1991).Applicant
• Frippiat et al., “First Genomic Sequence of a Human Ig Variable Lambda Gene Belonging to Subgroup III,” Nucleic Acids Research, 18:7134 (1990).Applicant
• Gaulton et al., “Idiotypic Mimicry of Biological Receptors” Ann. Rev. Immunol., 4:253-280 (1986).Applicant
• Gearing et al., “A Simple Sensitive Bioassay for Interleukin-1 Which is Unresponsive to 103 U/ml of Interleukin-2,” J. Immunol. Methods, 99:7-11 (1987).Applicant
• Gendler et al., “A Highly Immunogenic Region of a Human Polymorphic Epithelial Mucin Expressed by Carcinomas Is Made Up of Tandem Repeats,” J. Biol. Chem., 263:12820-12823 (1988).Applicant
• Gherardi et al., “A Single-Step Procedure for Cloning and Selection of Antibody-Secreting Hybridomas,” J. Immunol. Meth., 126:61-68 (1990).Applicant
• Goldstein,G., “Overview of the development of Orthoclone OKT3: monoclonal antibody for therapeutic use in transplantation,” Transplant Proc (United States), 19 (2 Suppl 1):1-6 (Apr., 1987).Applicant
• Goodnow et al., “Altered Immunoglobulin Expression and Functional Silencing of Self-Reactive B Lymphocytes in Transgenic Mice,” Nature, 334:676-682 (1988).Applicant
• Gorick et al., “Three Epitopes on the Human Rh Antigen D Recognized by 125I-Labelled Human Monoclonal IgG Antibodies,” Vox. Sang., 55:165-170 (1988).Applicant
• Guarante, L. et al., “Technique for Expressing Eukaryotic Genes in Bacteria,” Biotechnology (United States), 24:261-3 (1992).Applicant
• Gum et al., “Molecular Cloning of cDNAs Derived from a Novel Human Intestinal Mucin Gene,” Biochemical Biophysical Research Commun., 171:407-415 (1990).Applicant
• Gössow et al., “Direct Clone Characterization from Plaques and Colonies by the Polymerase Chain Reaction,” Nucleic Acids Research, 17:4000 (1989).Applicant
• Harris et al., “Therapeutic antibodies—the coming of age,” Trends Biotechnol (England), 11(2):42-4 (Feb., 1993).Applicant
• Hartley et al., “Elimination from Peripheral Lymphoid Tissues of Self-Reactive B Lymphocytes Recognizing Membrane-Bound Antigens,” Nature, 353:765-769 (1991).Applicant
• Hassan et al., “Prevalence of anti-Fab antibodies in patients with autoimmune and infectious diseases”, Clin. exp. Immunol. 89:423-426 (1992).Applicant
• Hawkins et al., “Selection of Phage Antibodies by Binding Affinity,” J. Mol. Biol., 226:889-896 (1992).Applicant
• Hird et al., in: Genes and Cancer, Chapter 17 (1990).Applicant
• Holmberg et al., “Natural Antibodies and Autoimmunity,” Immunol. Today, 6:356-357 (1985).Applicant
• Hoogenboom et al., “Multi-Subunit Proteins on the Surface of Filamentous Phage: Methodologies for Displaying Antibody (Fab) Heavy and Light Chains,” Nucleic Acids Research, 19:4133-4137 (1991).Applicant
• Huse et al., “Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda”, Science, 246:1275-1281 (1989).Applicant
• Huston et al., “Protein Engineering of Antibody Sites: Recovery of Specific Activity in an Anti-Digoxin Single-Chain Fv Analogue Produced in Escherichia coli,” Proc. Natl. Acad. Sci., USA, 85:5879-5883 (1988).Applicant
• Ichihara et al., “Organization of Human Immunoglobulin Heavy Chain Diversity Gene Loci,” Embo J., 7:4141-4150 (1988).Applicant
• International Search Report, PCT/GB92/02240.Applicant
• Jönsson et al., “Real Time Biospecific InterationAnalysis: The Integration of Surface Plasmon Resonance Detection, General Biospecific Interface Chemistry and Microfluidics into One Analytical System,” In: Real Time Biospecific Interaction, A. Turner (Ed.), JAI Press Ltd., San Diego, vol. 2, pp. 291-336 (1992).Applicant
• Jönsson et al., “Real-Time Biospecific Interaction Analysis Using Surface Plasmon Resonance and a Sensor Chip Technology,” Biotechniques, 11:620-627 (Nov., 1991).Applicant
• James, K. et al., “Human monoclonal antibody production: Current status and future prospects,” J. Immunological Methods, 100:5-40 (1987).Applicant
• Jerome et al., “Adenocarcinoma Reactive Cytotoxic T Lymphocytes Recognize an Epitope Present on the Protein Core of Epithelial Mucin Molecules”, Cellular Immunity and the Immunotherapy of Cancer, pp. 321-328 (1990).Applicant
• Johnsson et al., “Immobilization of Proteins to a Carboxymethlydextran-Modified Gold Surface for Biospecific Interaction Analysis in Surface Plasmon Resonance Sensors,” Anal. Biochem., 198:268-277 (1991).Applicant
• Kang et al., “Linkage of recognition and replication functions by assembling combinatorial antibody Fab libraries along phage surface”, Proc. Natl. Acad. Sci. USA, 88:4363-4366 (1991).Applicant
• Karlsson et al., “Kinetic Analysis of Monoclonal Antibody-Antigen Interactions With A New Biosensor Based Analytical System,” J. Immunol. Methods, 145:229-240 (1991).Applicant
• Kettleborough et al., “Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation,” Protein Eng (England), 4 (7):773-83 (Oct., 1991).Applicant
• Kim, J.G and Abeyounis, C.J., “Monoclonal Rat Antibodies To Rat Carcinoembryonic Antigen,” Immunological Investigations, 17(1):41-48 (1988).Applicant
• Kim, J.G. and Abeyounis, C.J., “Isolation and Characterization of Rat Carcinoembryonic Antigen,” Int. Arch. Allergy Appl. Immunol., 92:43-49 (1990).Applicant
• Klobeck et al., “Subgroup IV of Human Immunoglobulin K Light Chains is Encoded by a Single Germline Gene,” Nucleic Acids Research, 13:6515-29 (1985).Applicant
• Leusch et al., “Failure to demonstrate TNF α-specific autoantibodies in human sera by ELISA and Western blot”, Journal of Immunological Methods, 139:145-147 (1991).Applicant
• Lydyard et al., “The Antibody Repertoire of Early Human B Cells I. High Frequency of Autoreactivity and Polyreactivity,” Scand J. Immunol., 31:33-43 (1990).Applicant
• Mach et al., “Statistical Determination of the Average Values of the Extinction Coefficients of Tryptophan and Tyrosine in Native Proteins,” Anal. Biochem., 200:74-80 (1992).Applicant
• Malthiéry et al., “Primary Structure of Human Thyroglobulin Deduced from the Sequence of Its 8448-Base Complementary DNA,” Eur. J. Biochem.,165:491-498 (1987).Applicant
• Marks et al., “By-Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling”, Bio/Technology, 10:779-783 (1992).Applicant
• Marks et al., “By-passing Immunization Human Antibodies from V-gene Libraries Displayed on Phage”, J. Mol. Biol., 222:581-597 (1991).Applicant
• Marks et al., “Oligonucleotide Primers For Polymerase Chain Reaction Amplification of Human Immunoglobulin Variable Genes and Design of Family-Specific Oligonucleotide Probes,” Eur. J. Immunol., 21:985-991 (1991).Applicant
• Matsuda et al., “Organization of Variable Region Segments of the Human Immunoglobulin Heavy Chain: Duplication of the D5 Cluster within the Locus and Interchromosomal Translocation of Variable Region Segments,” EMBO J., 9:2501-2506 (1990).Applicant
• Matthyssens et al., “Structure and Multiplicity of Genes for the Human Immunoglobulin Heavy Chain Variable Region,” Proc Natl Acad. Sci., USA, 77:6561-6565 (1980).Applicant
• McCafferty et al., “Phage antibodies: filamentous phage displaying antibody variable domains”, Nature 348:552-554 (1990).Applicant
• Miller et al., “A Monoclonal Autoantibody That Promotes Central Nervous System Remyelination in a Model of Multiple Sclerosis is a Natural Autoantibody Encoded by Germline Immunoglobulin Genes,” J. Immunol, 154:2460-2469 (1995).Applicant
• Milstein, F.R.S., “Antibodies: a paradigm for the biology of molecular recognition”, Proc. R. Soc. London B, 239:1-16 (1990).Applicant
• Moynier et al., “The B Cell Repertoire in Rheumatoid Arthritis. I. Frequency of EBV-Indicible Circulating Precursors Producing Autoantibodies”, Journal of Autoimmunity, 4:631-649 (1991).Applicant
• Munro et al., “An Hsp70-like Protein in the ER: Identity with the 78 kd Glucose-Regulated Protein and Immunoglobulin Heavy Chain Binding Protein,” Cell, 46:291-300 (Jul., 1986).Applicant
• Nemazee et al., “Clonal Deletion of B Lymphocytes in a Transgenic Mouse Bearing Anti-MHC Class I Antibody Genes,” Nature, 337:562-566 (1989).Applicant
• Nossal, “Immunologic Tolerance: Collaboration Between Antigen and Lymphokines”, Science, 245:147-153 (1989).Applicant
• Orencole et al., “Characterization of a Subclone (D10S) of the D10.G4.1 Helper T-Cell Line which Proliferates to Attomolar Concentrations of Interleukin-1 in the Absence of Mitogens,” Cytokine (United States), 1(1):14-22 (Nov., 1989).Applicant
• Osband et al., “Problems in the investigational study and clinical use of cancer immunotherapy,” Immunol Today (England), 11 (6):193-5 (Jun., 1990).Applicant
• Pargent et al., “The Human Immunoglobulin χ Locus. Characterization of the duplicated O Regions,” Eur. J. Immunol., 21:1821-7 (1991).Applicant
• Parmley et al., “Antibody-selectable filamentous fd phage vectors: affinity purification of target genes”, Gene, 73:305-318 (1988).Applicant
• Pech et al., “Organization and Evolution of a Gene Cluster for Human Immunoglobulin Variable Regions of the Kappa Type,” J. Mol Biol, 176:189-204 (1984).Applicant
• Portolano et al., “A Human FAB Fragment Specific for Thyroid Peroxidase Generated by Cloning Thyroid Lymphocyte-Derived Immunoglobulin Genes in a Bacteriophage Lambda Library”, Biochemical and Biophysical Research Communications, 179(1):372-377 (1991).Applicant
• Price et al., “Immunological and Structural Features of the Protein Core of Human Polymorphic Epithelial Mucin,” Molec. Immunol., 27:795-802 (1990).Applicant
• Queen et al., “A humanized antibody that binds to the interleukin 2 receptor,” Proc Natl Acad Sci U S A (United States), 86 (24):10029-33 (Dec., 1989).Applicant
• Rath et al., “An Inhibition Enzyme Immunoassay for Estimating Relative Antibody Affinity and Affinity Heterogeneity,” J. Immunol Methods, 106:245-249 (1988).Applicant
• Reichmann et al., “Reshaping human antibodies for therapy,” Nature (England), 332 (6162):323-7 (Mar., 1988).Applicant
• Rossomando et al., “Studies on the Bacteroiphage f1 I. Alkali-induced Disassembly of the Phage into DNA and Protein,” J. Mol. Biol., 36:387-399 (1968).Applicant
• Russell et al., “Peripheral Deletion of Self-Reactive B Cells,” Nature, 354:308-311 (1991).Applicant
• Saiki et al., “Enzymatic Amplification of β-Globin Genomic Sequences and Restriction Site Analysis for Diagnosis of Sickle Cell Anemia,” Science, 230:1350-1354 (1985).Applicant
• Sanger et al., “DNA Sequencing With Chain-Terminating Inhibitors,” Proc Natl. Acad Sci, USA, 74:5463-5467 (1977).Applicant
• Sanz et al., “Nucleotide Sequences of Eight Human Natural Autoantibody vH Regions Reveals Apparent Restricted Use of VH Families”, The Journal of Immunology, 142(11):4054-4061 (1989).Applicant
• Sanz et al., “The Smaller Human VH Gene Families Display Remarkably Little Polymorphism,” EMBO J., 8:3741-3748 (1989).Applicant
• Scott et al., “Clonal Characterization of the Human IgG Antibody Repertoire to Haemophilus influenzae Type b Polysaccharide,” J Immunol, 47:4007-13 (1991).Applicant
• Scott et al., “Searching for Peptide Ligands with an Epitope Library,” Science, 249:386-390 (1990).Applicant
• Sege et al., “Use of Anti-idiotypic Antibodies as Cell-Surface Receptor Probes” Proc. Natl. Acad. Sci, USA, 75:2443-2447 (1978).Applicant
• Sekigawa et al., “Characterization of Autoantibodies to the CD4 Molecule in Human Immunodeficiency Virus Infection”, Clinical Immunology and Immunopathology, 58:145-153 (1991).Applicant
• Short et al., “λ ZAP: a bacteriophage λ expression vector with in vivo excision properties”, Nucleic Acids Research, 16(15):7583-7600 (1988).Applicant
• Sims et al., “Cloning the Interleukin 1 Receptor from Human T Cells,” Proc. Natl. Acad. Sci., USA, 86:8946-8950 (1989).Applicant
• Smith, “Filamentous Fusion Phage: Novel Expression Vectors That Display Cloned Antigens on the Virion Surface”, Science, 228:1315-1317 (1985).Applicant
• Steinman et al., “Prospects for Specific Immunotherapy in Myasthenia Gravis,” FASEB J., 4:2726-2731 (1990).Applicant
• Takii et al., “Interleuki-1 Up-Regulates Transcription of Its Own Receptor in a Human Fibroblast Cell Line TIG-1: Role of Endogenous PGE2 and cAMP,” Eur. J. Immunol., 22:1221-1227 (1992).Applicant
• Tomlinson et al., “The Repertoire of Human Germline VH Sequences Reveals about Fifty Groups of VH Segments with Different Hypervariable Loops,” J. Mol. Biol., 227:776-798 (1992).Applicant
• Tsunetsugu-Yokota et al., “Expression of an immunogenic region of HIV by a filamentous bacteriophage vector”, Gene, 99:261-265 (1991).Applicant
• Waldmann TA, “Monoclonal antibodies in diagnosis and therapy,” Science (United States), 252 (5013):1657-62 (Jun., 1991).Applicant
• Ward et al., “Binding Activities of a Repertoire of Single Immunoglobulin Variable Domains Secreted from Escherichia coli,” Nature, 341:544-546 (1989).Applicant
• Williams et al., “The Immunoglobulin Superfamily-Domains for Cell Surface Recognition,” Ann. Rev. Immunol., 6:381-405 (1988).Applicant
• Winter et al., “Man-made antibodies”, Nature 349:293-299 (1991).Applicant
• Wraith et al., “T Cell Recognition as the Target for Immune Intervention in Autoimmune Disease,” Cell, 57:709-715 (1989).Applicant
• Yativ et al., “The Detection of Antithyroglobulin Activity in Human Serum Monoclonal Immunoglobulins (Monoclonal Gammopathies)”, Immunol. Res., 12:330-337 (1993).Applicant
• Barbas, et al., “Assembly of combinatorial antibody libraries on phage surfaces: The gene III site”, PNAS USA, 88:7978-7982 (1991).Applicant
• Abstract, Sioud-M. et al., “Characterization of naturally occurring autoantibodies against tumour necro is factor-alpha (TNF-alpha): in vitro function and precise epitope mapping in phage epitope library”, Clin-Exp-Immunol., 98(3):520-525 (1994).Applicant
• Abstract, Tsuchiyama-L, et al., “Comparison of anti-TNF alpha autoantibodies in plasma and from EBV transformed lymphocytes of autoimmune and normal individuals”, Human Antibodies Hybridomas, 6(2):73-76 (1995).Applicant
• Abbas et al., “Cellular and Molecular Immunology,” Saunders, Third Edition, p. 412 (1997).Applicant
• Alberts et al., “Molecular Biology of the Cell,” Garland Publications, Third Edition, p. 96 (1994).Applicant
• Avrameas and Ternynck, “Natural Antibodies,” in Delves, P., and I. Roitt, The Encyclopedia of Immunology, Second Edition, Academic Press, pp. 1806-1809 (1998).Applicant
• Barbas et al., “Combinatorial Immunoglobulin Libraries on the Surface of Phage (Phabs): Rapid Selection of Antigen Specific Fabs,” Methods: Companion Methods Enzymol., 2:119 (1991).Applicant
• Beidler et al., “Cloning and High Level Expression of a Chimeric Antibody with Specificity for Human Carcinoembryonic Antigen,” J. Immunology, 141:4053-4060 (1988).Applicant
• Berborowicz and Jaroszewski, “Carcinoembryonic Antigen as an Autoantigen,” Immunol. Ser., 52:65-83 (1982).Applicant
• Berzofsky et al., “Antigen-Antibody Interactions and Monoclonal Antibodies,” in Paul, W., Fundamental Immunology, Second Edition, Chapter 12, p. 332 (see also, Fourth Edition, 1994, [1999] chapter 4, p. 91.Applicant
• Boerner et al., “Production of Antigen-Specific Human Monoclonal Antibodies From In Vitro-Primed Human [Splenocytes],” J. Immunol., 147:86-95 (1991).Applicant
• Breitling et al., “A Surface Expression Vector for Antibody Screening,” Gene, 104:147-153 (1991).Applicant
• Burton et al., “A Large Array of Human Monoclonal Antibodies to Type 1 Human Immunodeficiency Virus from Combinatorial Libraries of Asymptomatic Seropositive Individuals,” Proc. Natl. Acad. Sci., 88:10134-10137 (1991).Applicant
• Chang et al., “Expression of Antibody Fab Domains on Bacteriophage Surfaces: Potential Use of Antibody Selection,” J. Immunol., 1047:3610-3614 (1991).Applicant
• Cohen, P.L., “Systemic Autoimmunity,” in Paul, W., Fundamental Immunology, Fourth Edition, Lippincott-Raven, p. 1608 [1067].Applicant
• Delves, P.J., “Autoimmunity,” in Delves, P. and I. Roitt, The Encyclopedia of Immunology, Second Edition, Academic Press, p. 292 (1998).Applicant
• Dighiero et al., “Naturally Occurring Autoantibodies Against Nine Common Antigens in Human Sera,” J. Immunol., 218[128]:2788-2792 (1982).Applicant
• Fomsgaard et al., “Auto-antibodies to Tumor Necrosis Factor in Healthy Humans and Patients with Inflammatory Diseases and Gram-Negative Bacterial Infections,” Scand. J. Immunol., 30:219-223 (1989).Applicant
• Golub, E., and Green, D., “Immunology: A Synthesis,” Sinauer Associates, Second Edition, p. 531 (1991).Applicant
• Golub, E., “The Limits of Medicine: How Science Shapes our Hope for the Cure,” Times Books/Random House, p. 117-120 (1994).Applicant
• Gram et al., “In vitro Selection and Affinity maturation of Antibodies from a Naive Combinatorial Immunoglobulin Library,” Proc. Natl. Acad. Sci. (USA), 89:3576-3580 (1992).Applicant
• Griffiths et al., “Human Anti-Self Antibodies with High Specificity from Phage Display Libraries,” EMBO J., 12:725-734 (1993).Applicant
• Griffiths et al., “Isolation of High Affinity Human Antibodies Directly from Large Synthetic Repertoires,” EMBO J., 13:3245-3260 (1994).Applicant
• Guilbert et al., “Naturally Occurring Antibodies Against Nine Common Antigens in Human Sera,” J. Immunol., 128:2779-2787 (1982).Applicant
• Hartman and Wright, “Identification of Autoantibodies Specific for the Neutrophil Adhesion Glycoproteins CD11b/CD18 in Patients with Autoimmune Disease [Neutropenia],” Blood, 78:1096-1104 (1991).Applicant
• Hirohata et al., “Frequency Analysis of Human Peripheral Blood B Cells Producing IgM-Rheumatoid Factor,” J. Immunol., 145:1681-1686 (1990).Applicant
• Hoogenboom et al., “Building Antibodies From Their Genes,” Rev. Fr. Transfus. Hemobiol., 36:19-47 (1993).Applicant
• Huse, “Combinatorial Antibody Expression Libraries in Filamentous Phage,” Chapter 5 of Antibody Engineer, Borrebaeck (ed.), W.H. Freeman and Co. N.Y. (1992).Applicant
• Huston et al., “Protein Engineering of Single-Chain Fv Analogs and Fusion Proteins,” Methods in Enzymology, 203:46-88 (1991).Applicant
• Kaushik et al., “Comparative Analysis of Natural Antibody Specificities Among Hybridomas Originating from spleen and Peritoneal Cavity of Adult NZB and BALB/c Mince,” Scand. J. Immunol., 27:461-471 (1988).Applicant
• Klein and Horejsi, “Immunology” [Chapter 20, “Immunological Tolerance”], Blackwell Scientific, Second Edition, p. 527 (1997).Applicant
• Koga et al., “Mouse-Human Chimeric Monoclonal Antibody to Carcinoembryonic Antigen (CEA): In Vitro and In Vivo Activities,” Hybridoma, 9:43-56 (1990).Applicant
• Landsteiner, K., “The Specificity of the Immune Response,” quoted in Golub, E., Immunology: A Synthesis, Sinauer Associates, p. 19-25, [1991 book] (1987).Applicant
• Logtenberg et al., “Analysis of the Human Tonsil B Cell Repertoire by Somatic Hybridization: Occurrence of Both “Monospecific” and “Multispecific” (auto) Antibody-Secreting Cells,” Eur. J. Immunol., 17:855-859 (1987).Applicant
• Mamula et al., “The Specificity of Human Anti-Cycochrome c Autoantibodies that Arise in Autoimmune Disease,” J. Immunol., 144:1835-1840 (1990).Applicant
• Marks et al., “Molecular Evolution of Proteins on Filamentous Phage,” J. Biol. Chem., 267:16007-16010 (1992).Applicant
• McHeyzer-Williams et al., “Clonal Analysis of Autoantibody-Producing Cell Precursors in the Preimmune B Cell Repertoire,” J. Immunol., 141:4118-4123 (1988).Applicant
• Mullinax et al., “Identification of Human Antibody Fragment Clones Specific For Tetanus Toxoid in a Bacteriophage λ Immunoexpression Library,” Proc. Natl. Acad. Sci., USA, 87:8095-8099 (1990).Applicant
• Nossal, G.V.J., “Cellular Mechanisms of Immune[ologic] Tolerance,” Ann. Rev. Immunol., 1:33-62 (1983).Applicant
• Nossal, G.V.J., “Molecular and Cellular Aspects of Immunologic Tolerance,” Eur. J. Biochem., 202:729-737 (1991).Applicant
• Neumaier et al., “Cloning of the Genes for T84.66, an Antibody That Has a High Specificity and Affinity for Carcinoembryonic Antigen, and Expression of Chimeric Human/Mouse T84.66 Genes in Myeloma and Chinese Hamster Ovary Cells,” Cancer Research, 50:2128-2134 (1990).Applicant
• Perelson, A.S., “Immune Network Theory,” Immunol. Rev., 110:5-36 (1989).Applicant
• Persson et al., “Generation of Diverse High-Affinity Human Monoclonal Antibodies by Repertoire Cloning,” Proc. Natl. Acad. Sci., 88:2432-2436 (1991).Applicant
• Ruf et al., “Various Expressions of a Unique Anti-Human Thyroglobulin Antibody Repertoire in Normal State and Autoimmune Disease,” Blood, 78:1096-1104 (1991).Applicant
• Smith et al., “Phage Display,” Chem. Rev., 97:391-410 (1997).Applicant
• Svenson et al., “IgG Autoantibodies Against Interleukin 1α in Sera of Normal Individuals,” Scand. J. Immunol., 29:489-492 (1989).Applicant
• Ura et al., “Studies on Circulating Antibody Against Carcinoembryonic Antigen (CEA) and CEA-like Antigen in Cancer Patients,” Cancer Letters, 25:283-295 (1985).Applicant
• Waterhouse et al., “Combinatorial Infection and in Vivo Recombination: A Strategy for Making Large Phage Antibody Repertoires,” Nucl. Acids Res., 21:2265-2266 (1993).Applicant
• Wilson and Stanfield, “Antibody-antigen Interactions: New Structures and New Conformational Changes,” Curr. Opin. Structural Biol., 4:857-867 (1994).Applicant
• Winter et al., “Making Antibodies by Phage Display Technology,” Annu. Rev. Immunol., 12:433-455 (1994).Applicant
• Complaint filed Apr. 23, 1999.Applicant
• First Amended Complaint filed May 6, 1999.Applicant
• Defendant Cambridge Antibody Technology, Limited's Motion to Dismiss Plaintiff MorPhosys AG's Complaint filed Jun. 8, 1999.Applicant
• Response of Plaintiff MorphoSys AG to Cambridge Antibody Technology Ltd.'s First Set of Interrogatories and Request for Production of Documents and Things filed Oct. 18, 1999.Applicant
• Plaintiff's Supplemental Answer to Interrogatory No. 2.Applicant
• Response of Plaintiff MorphoSys AG to Cambridge Antibody Technology Ltd.'s First Set of Interrogatories and Request for Production of Documents and Things filed Mar. 27, 2000.Applicant
• Response of Plaintiff MorphoSys AG to Cambridge Antibody Technology Ltd.'s Second Set of Interrogatories filed Jul. 3, 2000.Applicant
• Response of MorphoSys AG to Cambridge Antibody Technology's Third Set of Interrogatories filed Aug. 14, 2000.Applicant
• Declaration Of Edward S. Golub, Ph.D. In Support Of MorphoSys' Motion For Partial Summary Judgment of Noninfringement filed Sep. 1, 2000.Applicant
• Edward S. Golub, Ph.D. Curriculum Vitae.Applicant
• Expert Report of Edward S. Golub, Ph.D. dated 6/00 (with Exhibit 1 E.S. Golub Curriculum Vitae Exhibit 2 E.S. Golub Validity Report and Exhibit 3 Declaration of E.S. Golub regarding Immunological Concepts).Applicant
• Rebuttal Expert Report of Edward S. Golub, Ph.D.Applicant
• Reply of Edward S. Golub, Ph.D. to Rebuttal Expert Reports of Edward P. Cohen, M.D. and Ronald H. Jackson, Ph.D. dated Aug. 1, 2000.Applicant
• Declaration Of Carlos F. Barbas III, Ph.D. In Support Of MorphoSys' Motion For Partial Summary Judgment Of Noninfringement filed Sep. 1, 2000.Applicant
• Carlos F. Barbas III, Ph.D. Curriculum Vitae.Applicant
• Hoermann, et al., T3 releasing activity by Graves' sera from Graves' thyroid in vitro, Acta Endrocrinologica, 1986, 111:487-493.Applicant
• Hoogenboom et al., “Building Antibodies From Their Genes”, Immunol. Rev., vol. 130 p. 41-68 (1992).Applicant
• Larrick et al., “Recombinant Antibodies”, Hum. Antibod. Hybridomas, vol. 2, p. 172-189 (1991).Applicant
• Wallukar, G., et al., “Autoantikörper gegen den β1-adrenergen Rezeptor bei Myokarditis und dilatativer Kardiomyopathie: Lokalisation von zwei Epitopen”, Z. Kardiol, 81:Suppl. 4, 79-83 (1992).Applicant
• Complaint, filed Apr. 23, 1999; (5 pages) Morphosys AG v Cambridge Antibody Limited, Case No. 1:99CV01012; Judge James Robertson.Applicant
• First Amended Complaint filed May 6, 1999—(18 pages) Morphosys AG v Cambridge Antibody Limited, Case No. 1:99CV01012; Judge James Robertson.Applicant
• Defendant Cambridge Antibody Technology, Limited's Motion to Dismiss Plaintiff MorPhosys AG's Complaint filed Jun. 8, 1999 (4 pages) Morphosys AG v Cambridge Antibody Limited, Case No. 1:99CV01012; Judge James Robertson.Applicant
• Response of Plaintiff MorphoSys AG to Cambridge Antibody Technology Ltd.'s First Set of Interrogatories and Request for Production of Documents and Things filed Oct. 18, 1999 -(20 pages) Morphosys AG v Cambridge Antibody Limited, Case No. 1:99CV01012; Judge J. Robertson.Applicant
• Plaintiff's Supplemental Answer to Interrogatory No. 2 (9 pages) Morphosys AG v Cambridge Antibody Limited, Case No. 1:99CV01012; Judge James Robertson.Applicant
• Response of Plaintiff Morphosys AG to Cambridge Antibody Technology Ltd's First Set of Interrogatories and Request for Production of Documents and Things filed Mar. 27, 2000 (19 pages) Morphosys AG v Cambridge Antibody Limited, Case No. 1:99CV01012; Judge J Robertson.Applicant
• Response of Plaintiff Morphosys AG to Cambridge Antibody Technology Ltd's Second Set of Interrogatories filed Jul. 3, 2000 (3 pages) Morphosys AG v Cambridge Antibody Limited, Case No. 1:99CV01012; Judge James Robertson.Applicant
• Response of MorphoSys AG to Cambridge Antibody Technology's Third Set of Interrogatories filed Aug. 14, 2000 (4 pages) Morphosys AG v Cambridge Antibody Limited, Case No. 1:99CV01012; Judge James Robertson.Applicant
• Declaration of Edward S. Golub, Ph.D. In Support of MorphoSys' Motion for Partial Summary Judgment of Noninfringement filed Sep. 1, 2000- (6 pages) Morphosys AG v Cambridge Antibody Limited, Case No. 1:99CV01012; Judge James Robertson.Applicant
• Edward S. Golub, Ph.D. Curriculum Vitae (12 pages) Morphosys AG v Cambridge Antibody Limited, Case No. 1:99CV01012; Judge James Robertson.Applicant
• Expert Report of Edward S. Golub, Ph.D. dated 6/00 (with Exhibit 1 E. S. Golub Curriculum Vitae Exhibit 2 E. S. Golub Validity Report and Exhibit 3 Declaration of E.S. Golub regarding Immunological Concepts) (53 pages) Morphosys AG v Cambridge Antibody Limited, Case No. 1:99CV01012; Judge J Robertson.Applicant
• Rebuttal Expert Report of Edward S. Golub, Ph.D. (8 pages) Morphosys AG v Cambridge Antibody Limited, Case No. 1:99CV01012; Judge James Robertson.Applicant
• Reply of Edward S. Golub, PH.D. to Rebuttal Expert Reports of Edward P. Cohen, M.D. and Ronald H. Jackson, P.D., dated Aug. 1, 2000 (5 pages) Morphosys AG v Cambridge Antibody Limited, Case No. 1:99CV01012; Judge James Robertson.Applicant
• Declaration of Carlos F. Barbas III, Ph.D. in Support of MorphoSys' Motion for Partial Summary Judgment of Noninfringement filed Sep. 1, 2000—(3 pages) Morphosys AG v Cambridge Antibody Limited, Case No. 1:99CV01012; Judge James Robertson.Applicant
• Carlos F. Barbas III, Ph.D. Cirruculum Vitae (16 pages) Morphosys AG v Cambridge Antibody Limited, Case No. 1:99CV01012; Judge James Robertson.Applicant
• Trial Transcript—Edward Golub, Ph.D.—Mar. 21, 2001—Civil Action No. 99-1012 JR (pp. 623-637) Morphosys AG v Cambridge Antibody Limited, Case No. 1:99CV01012; Judge James Robertson.Applicant
• Trial Transcript—Edward Golub, Ph.D.—Mar. 22, 2001—Civil Action No. 99-1012 JR (a.m. session) (pp. 638-689) Morphosys AG v Cambridge Antibody Limited, Case No. 1:99CV01012; Judge James Robertson.Applicant
• Trial Transcript—Edward Golub, Ph.D.—Mar. 22, 2001—Civil Action No. 99-1012 (p.m. session) (pp. 698-721) Morphosys AG v Cambridge Antibody Limited, Case No. 1:99CV01012; Judge James Robertson.Applicant
• Trial Transcript—Carlos Barbas, Ph.D.—Mar. 22, 2001—Civil Action No. 99-1012 (pp. 766-777) Morphosys AG v Cambridge Antibody Limited, Case No. 1:99CV01012; Judge James Robertson.Applicant
• Trial Transcript—Carlos Barbas, Ph.D.—Mar. 26, 2001—Civil Action No. 99-1012 (a.m. session) (pp. 790-878). Morphosys AG v Cambridge Antibody Limited, Case No. 1:99CV01012; Judge James Robertson.Applicant
• Trial Transcript—Carlos Barbas, Ph.D.—Mar. 26, 2001—Civil Action No. 99-1012 (p.m. session) (pp. 883-911) Morphosys AG v Cambridge Antibody Limited, Case No. 1:99CV01012; Judge James Robertson.Applicant
• Trial Transcript, Closing Arguments of Attorney Hart, Mar. 28, 2001 (pp. 1306-1312). Morphosys AG v Cambridge Antibody Limited, Case No. 1:99CV01012; Judge James Robertson.Applicant
• Expert Report of Ronald Jackson, Ph.D., Dated Aug. 11, 2000 (20 pages) Morphosys AG v Cambridge Antibody Limited, Case No. 1:99CV01012; Judge James Robertson.Applicant
• Expert Report of Edward S. Cohen, Dated: Jun. 25, 2000 (37 pages) Morphosys AG v Cambridge Antibody Limited, Case No. 1:99CV01012; Judge James Robertson.Applicant
• Expert Rebuttal Report of Edward S. Cohen, Jul. 26, 2000 (13 pages) Morphosys AG v Cambridge Antibody Limited, Case No. 1:99CV01012; Judge James Robertson.Applicant
• Bachman et al., “Absence of co-stimulation and not the Intensity of TCR signaling is critical for the induction of T cell unresponsiveness in vivo”, Eur. J. Immunol., 1999.29:pp. 2156-2166.Applicant
• Batteaux. et al., “Transgenic Expression of Fas Ligand on Thyroid Follicular Cells Prevents Autoimmune Thyroiditis”, J. of Immunology, 2000, 164: 1681-1688.Applicant
• Better, et al., “Escherichia coli Secretion of an Active Chimeric Antibody Fragment”, Science, 240:1041-1043.Applicant
• Breitling, et al., “A surface Expression Vector or antibody screening”, Gene, 104 (1991), pp. 147-153.Applicant
• Bruin, et al., “Neutrophil Antibody Specificity in Different Types of Childhood Autoimmune Neutropenia”, Blood, No. 5, (Sep. 1) 1999, pp. 1797-1802.Applicant
• Chen, et al., “A testicular antigen abberrantly expressed in human cancers detected by autologous antibody Screening”, PNAS USA, vol. 94, pp. 1914-1918, Mar. 1997 Immunology.Applicant
• Choudhury, et al., “Disruption of T Cell Tolerance to Self-Immunoglobulin Causes Polyclonal B Cell Stimulation Followed by Inactivation of Responding Autoreactive T Cells”, The Journal of Immunology, 2000, 164: pp. 1713-1721.Applicant
• Glockshuber, et al., “A Comparison of Strategies to Stabilize Immunoglobulin FV Fragments”, Biochem., 29:1362-1367.Applicant
• Gure et al., “SSX: A Multigene Family With Several Members Several Members Transcribed in Normal Tests and Human Cancer”, Int. J. Cancer, 72:965-971, (1997).Applicant
• Janeway, et al., “The interaction f the antibody molecule with specific antigen”, Chapter 3, Immunology, CB Publications, (1999), pp. 86-93.Applicant
• Janeway, et al., “Selection of B cells” Chapter 6, Immunology, CB Publications, (1999), pp. 209-213.Applicant
• Janeway, et al., “Tolerance and loss of tolerance to self tissues”, Chapter 13, Immunology, CB Publications, (1999), pp. 520-532.Applicant
• Knappik, et al., “Fully Synthetic Combinatorial Antibody Libraries (HuCal) Based on Modular Consensus Frameworks and CDRs Randomized with Trinuclotides”, J. Mol. Biol., (2000) 200:pp. 57-86.Applicant
• Kotera, et al., “Humoral Immunity Against a Tandem Repeat Epitope of Human Mucin MUC-1 in Sera from Breast, Pancreatic, and Colon Cancer Patients”, Cancer Res., 54, 2856-2860.Applicant
• Kuo, et al., “Crossreactive B cells are present during a primary but not secondary response in BALB/c mice expressing a bcl-2 transgene”, “Molecular Immunology”, 36 (1999) pp. 471-479.Applicant
• Kuwahara, et al., “Autoantibody against Testosterone in a woman with Hypergonadotropic Hypogonadism”, J. Clin. Endocrin. & Metabolism, vol. 85, pp. 14-16.Applicant
• Maxwell, et al., “Danger and OX40 Receptor Signaling Synergize to Enhance Memory T Cell Survival by Inhibiting Peripheral Deletion”, J. Immunology, 2000. 164: pp. 107-112.Applicant
• Morgan, et al., “Antigen Concentration and Precursor Frequency Determine the Rate of CD8+ T Cell Tolerance to Peripherally Expressed Antigens”, J. of Immunology, 163:pp. 723-727.Applicant
• Oosterwegel, et al., “CTLA-4 and T Cell activation”, Current Opinion in Immunology, 1999, pp. 294-300.Applicant
• Dr. Noel Rose, “The Uses of AutoAntibodies”, in Peter & Schoefeld, AutoAntibodies at xxvii (1996).Applicant
• Sahin et al., “Human neoplasms elicit multiple specific Immune response in the autologous host”, PNAS USA vol. 92, pp. 11810-11813, Dec. 1995.Applicant
• Sahin et al., “Serological identification of human tumor antigens”, Cancer, 709-716.Applicant
• Sakaguchi, et al., “Regulatory T Cells Key Controllers of Immunologic Self-Tolerance”, Cell, pp. 455-458.Applicant
• Scanlan, et al., “Characterization of Human Colon Cancer Antigens Recognized by Autologous Antibodies”, Int. J. Cancer, 76:652-658 (1998).Applicant
• Skerra, et al., “Assembly of a Functional Immunoglobulin Fv Fragment in Escherichia coli”, Science, vol. 240, pp. 1038-1041.Applicant
• Türeci, et al., “Molecular Definition of a Novel Human Galectin Which is Immumogenic in Patients with Hodgkins Disease”, J. of Biol. Chem., vol. 272, No. 10, Mar. 7, 1997, pp. 6416-6422.Applicant
• Türeci et al., “Identification of a meiosis-specific protein as a member of the class of cancer/testis antigens”, PNAS USA, vol. 95:pp. 5211-5216, Apr. 1998, Immunology.Applicant
• Türeci et al., “Human carbonic anhydrase XII: cDNA cloning, expression, and chromosal localization of a carbonic anhydrase gene that is overexpressed in some renal cell cancers”, PNAS USA, vol. 95, pp. 7608-7613, Jun. 1998.Applicant